ANI Pharmaceuticals Acquires Rights to Testosterone Gel 1%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ANI Pharma (ANIP) Acquires NDA for Testosterone Gel 1% from Teva (TEVA)
May 13, 2015 8:02 AM EDTANI Pharmaceuticals, Inc.(NASDAQ: ANIP) announced that it has acquired the approved new drug application for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals (NASDAQ: TEVA). Upon commercialization, ANI will pay Teva up to... More
